Repeated fMRI using iron oxide contrast agent in awake, behaving macaques at 3 Tesla

被引:204
作者
Leite, FP [1 ]
Tsao, D
Vanduffel, W
Fize, D
Sasaki, Y
Wald, LL
Dale, AM
Kwong, KK
Orban, GA
Rosen, BR
Tootell, RBH
Mandeville, JB
机构
[1] MIT, Dept Nucl Engn, Cambridge, MA 02139 USA
[2] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA
[3] Catholic Univ Louvain, Neuro & Psychofysiol Lab, B-3000 Louvain, Belgium
[4] Massachusetts Gen Hosp, Charlestown, MA 02129 USA
[5] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA
关键词
D O I
10.1006/nimg.2002.1110
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Iron oxide contrast agents have been employed extensively in anesthetized rodents to enhance fMRI sensitivity and to study the physiology of cerebral blood volume (CBV) in relation to blood oxygen level-dependent (BOLD) signal following neuronal activation. This study quantified the advantages of exogenous agent for repeated neuroimaging in awake, nonhuman primates using a clinical 3 Tesla scanner. A monocrystalline iron oxide nanoparticle (MION) solution was injected at iron doses of 8 to 10 mg/kg in two macaque monkeys. Adverse behavioral effects due to contrast agent were not observed in either monkey using cumulative doses in excess of 60 mg/kg. Relative to BOLD imaging at 3 Tesla, MION increased functional sensitivity by an average factor of 3 across the brain for a stimulus of long duration. Rapid stimulus presentation attenuated MION signal changes more than BOLD signal changes, due to the slower time constant of the blood volume response relative to BOLD signal. Overall, the contrast agent produced a dramatic improvement in functional brain imaging results in the awake, behaving primate at this field strength. (C) 2002 Elsevier Science (USA).
引用
收藏
页码:283 / 294
页数:12
相关论文
共 47 条
[11]  
Edwards CQ, 2000, HEMOCHROMATOSIS: GENETICS, PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT, P312
[12]  
Enochs WS, 1999, JMRI-J MAGN RESON IM, V9, P228, DOI 10.1002/(SICI)1522-2586(199902)9:2<228::AID-JMRI12>3.3.CO
[13]  
2-B
[14]  
Friston K., 1995, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]
[15]  
Guyader D, 2000, HEMOCHROMATOSIS: GENETICS, PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT, P219
[16]   Mapping of somatosensory cortices with functional magnetic resonance imaging in anaesthetized macaque monkeys [J].
Hayashi, T ;
Konishi, S ;
Hasegawa, I ;
Miyashita, Y .
EUROPEAN JOURNAL OF NEUROSCIENCE, 1999, 11 (12) :4451-4456
[17]  
Hershko C, 2000, HEMOCHROMATOSIS: GENETICS, PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT, P339
[18]   Stimulus-dependent BOLD and perfusion dynamics in human V1 [J].
Hoge, RD ;
Atkinson, J ;
Gill, B ;
Crelier, GR ;
Marrett, S ;
Pike, GB .
NEUROIMAGE, 1999, 9 (06) :573-585
[19]   A FUNCTIONALIZED SUPERPARAMAGNETIC IRON-OXIDE COLLOID AS A RECEPTOR DIRECTED MR CONTRAST AGENT [J].
JOSEPHSON, L ;
GROMAN, EV ;
MENZ, E ;
LEWIS, JM ;
BENGELE, H .
MAGNETIC RESONANCE IMAGING, 1990, 8 (05) :637-646
[20]   Physiological basis for BOLD MR signal changes due to neuronal stimulation: Separation of blood volume and magnetic susceptibility effects [J].
Kennan, RP ;
Scanley, BE ;
Innis, RB ;
Gore, JC .
MAGNETIC RESONANCE IN MEDICINE, 1998, 40 (06) :840-846